Kenvue Inc.
Kenvue Reports Q1 2026 Earnings Beat with 4.5% Net Sales Increase
Summary
Kenvue Inc. announced its financial results for the fiscal first quarter ended March 29, 2026, reporting a 4.5% increase in net sales, driven by organic sales growth of 0.7% and a foreign currency benefit of 3.8%. The company saw improvements in gross profit margin, operating income margin, and earnings per share (EPS), with diluted EPS increasing 47% to $0.25 and adjusted diluted EPS increasing 33% to $0.32. Kenvue also provided an update on the pending transaction with Kimberly-Clark and the 2026 Restructuring Initiative.
Profitelligence Alerts
Get alerts for KVUE
Be first to know when Kenvue Inc. files with the SEC.
Filing Categories
Advertisement
About Kenvue Inc.
Kenvue Inc. is a consumer healthcare and pharmaceutical company. It focuses on delivering a range of health-centric products, spanning hygiene, pain relief, and other wellness categories. With deep-rooted expertise in pharmaceuticals, Kenvue Inc. targets the health and wellness needs of individuals, providing both prescription and over-the-counter solutions. The company has established itself as a vital entity in the consumer health sector, significantly impacting community health standards and individual lives. Positioned in the pharmaceutical industry, Kenvue Inc. collaborates with healthcare providers to enhance its product reach and efficacy. Its broad portfolio includes well-known brands and formulations that are trusted globally by consumers seeking reliable health solutions. As a player in this sector, Kenvue Inc. contributes to the enhancement of public health, highlighting its prominence in both domestic and international markets.
Official SEC Documents
Advertisement